Pure Biologics S.A. stock (PLPURE000013): shares trade quietly in Warsaw ahead of next catalysts

Pure Biologics shares on the Warsaw Stock Exchange traded with limited price movement and modest volumes at the start of the week, as investors await fresh clinical or funding updates from the Polish antibody and aptamer specialist.

Pure Biologics shares on the Warsaw Stock Exchange started the new week with subdued trading, as the Polish biotech name saw only modest price and volume changes while the market waits for clearer signals on its development pipeline and financing path.

According to data from the Warsaw Stock Exchange referenced by Polish financial portal Bankier, the stock, which trades under the ticker PURE in Poland, most recently changed hands at around 1.86 PLN on the local market, with no unusually high turnover reported on that session.Bankier as of 06/01/2026

The stock traded at 1.86 PLN on 06/01/2026 on the Warsaw Stock Exchange, according to Bankier as of 06/01/2026.

As of: 01.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Pure Biologics
• Sector/industry: Biotechnology / drug discovery
• Headquarters/country: Wroc?aw, Poland
• Core markets: Poland and broader European biopharma research partnerships
• Key revenue drivers: Early-stage therapeutic programs, research collaborations and service projects in antibodies and aptamers
• Home exchange/listing venue: Warsaw Stock Exchange (PURE)
• Trading currency: PLN

Pure Biologics S.A.: core business model

Pure Biologics focuses on discovering and developing antibody- and aptamer-based therapeutics and provides related research services that generate revenue through development milestones and collaboration income.

What banks and research houses say about Pure Biologics S.A.

No verified analyst coverage was identified at the time of publication.

Conclusion

The start of the week brought only limited price movement for Pure Biologics on the Warsaw Stock Exchange, signaling a wait-and-see stance among local investors as they look for clearer news from the company. With no widely cited analyst research available, the market focus remains squarely on company disclosures, clinical progress and funding steps, which will likely determine how the stock trades around future catalysts.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.